Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.
Chelsie Monroe, MSN, APN, PMHNP-BC
Advertisement
Articles by Chelsie Monroe, MSN, APN, PMHNP-BC
Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.
The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.
Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.
Karl Doghramji, MD, FAASM, DFAPA, and Chelsie Monroe, MSN, APN, PMHNP-BC, conclude the discussion with advice for clinicians who treat patients with narcolepsy.
Experts on narcolepsy offer perspectives on non-pharmacologic interventions for pediatric patients with narcolepsy, including lifestyle changes.
Focusing on the case of a 9-year-old with excessive daytime sleepiness and sudden episodes of muscle weakness, the panel discusses the difficulty in diagnosing pediatric patients with narcolepsy.
Advertisement
Latest Updated Articles
Robust Efficacy and Decreased Side Effects with New Muscarinic Agent for Treating SchizophreniaPublished: July 13th 2025 | Updated:
Clinician Tips in Prescribing New Xanomeline-Trospium for SchizophreniaPublished: July 13th 2025 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Patent Issued for Rapid Blood Tests to Differentiate Schizophrenia and Bipolar Disorder
2
When Symptoms Are Not Necessarily Signs of Illness: Rethinking Synchronicity in Psychiatry
3
Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders
4
Should Solitude Be a Psychiatric Value?
5
